Christos Vaklavas,
MD
Languages Spoken: English, German, Modern Greek (1453-)
Throughout his career, Dr. Vaklavas has developed a series of research activities in breast cancer that span the entire spectrum from lab-based research to clinical trials. In the lab, his focus has been on translation (mRNA to protein) and the discovery of compounds that disrupt oncogenic translation. This research has been supported by a Young Investigator Award from ASCO and a Career Catalyst Award in Basic and Translational Research from Susan G Komen.
As the Physician Leader in Breast Cancer at Huntsman Cancer Institute, he oversees all clinical research conducted in the Institute pertaining to breast cancer. He oversees the clinical trials portfolio and serves as the Principal Investigator for many clinical trials including investigator-initiated studies that intend to bring the highly innovative basic science conducted at Huntsman Cancer Institute closer to clinical applications.
Clinical Locations
801-213-3200
Clinic 3A, Center for Breast Health
801-587-4241
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.4/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
July 20, 2021
HUNTSMAN CANCER CENTER
It would be hard to overstate our gratitude to Dr. Vaklavas. He has been our guiding light throughout my terrible cancer ordeal. He is a devoted listener and has never failed to respond to my questions, fears and concerns. He has always treated me with the utmost kindness, respect, and competence. He exhibits a humility that Illustrates what a magnificent man and doctor he is. His patients are very well served. Thank you to this extraordinary man and his wonderful staff. My husband and I will forever be in his debt.
UofU Patient
July 20, 2021
FARMINGTON HEALTH CENTER
Dr. V and anna area wonderful
UofU Patient
June 22, 2021
FARMINGTON HEALTH CENTER
dr voklovas is outstanding
UofU Patient
June 10, 2021
HUNTSMAN CANCER CENTER
He is fabulous. He took the time to research other conditions I have prior to my visit. Very caring, funny in a good way.
UofU Patient
May 31, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
May 28, 2021
HUNTSMAN CANCER CENTER
every thing was explained in terms I could understand.
UofU Patient
May 26, 2021
HUNTSMAN CANCER CENTER
I'm just upset that suddenly he was being paged or something and I felt rushed. I've been I such bad pain in my chest area as of the last 4 weeks and here I am being ignored again. Old CT scans don't show new anything. I need a nerve abalation on my ribs near my heart. the pain is getting worse. he kept getting calls and pages and I am wondering if a patient was having an all out emergancy because that usually never ever happens. I just get upset because I have to take so much time and effort get to these appointments and I feel cheated when I can't atleast have time to show my serious concerns . I just don't feel like they matter and that hurts my feelings very much. I get that people are paying and calling but o was rushed out of the office after that. also, the new people in the front registration area are rude and incompetent. Alwats goes to voicemail where as before that rarely Happened.
UofU Patient
May 24, 2021
HUNTSMAN CANCER CENTER
Dr V took a great deal of time to understand my concerns and discuss options and treatment plans. I felt respected and assured of a high quality of care.
UofU Patient
May 04, 2021
FARMINGTON HEALTH CENTER
Dr. Vaklavas and Nurse Anna are wonderful. They take care of me. But I won't ever go back to Farmington Huntsman again. It's toxic.
UofU Patient
May 03, 2021
FARMINGTON HEALTH CENTER
Excellent communication. Answered all question thoroughly. Very patient and understanding.
UofU Patient
April 23, 2021
HUNTSMAN CANCER CENTER
Both the doctor and the nurse had very positive and friendly personalities.
UofU Patient
March 25, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
March 20, 2021
HUNTSMAN CANCER CENTER
all good
UofU Patient
February 26, 2021
HUNTSMAN CANCER CENTER
this dr was very good at taking this experience down a couple of notches by his ability to make this situation not so worry some.
UofU Patient
February 22, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
February 10, 2021
HUNTSMAN CANCER CENTER
Both doctor and nurse were caring, never made me feel rushed, and answered all my questions & concerns with great knowledge and examples. Made me feel great!
UofU Patient
February 07, 2021
FARMINGTON HEALTH CENTER
I appreciated having my concerns listened to.
UofU Patient
February 06, 2021
HUNTSMAN CANCER CENTER
good experience
UofU Patient
January 31, 2021
HUNTSMAN CANCER CENTER
Dr Vaklavas was very thorough and caring.
UofU Patient
January 27, 2021
HUNTSMAN CANCER CENTER
Dr. Vaklvas and Torie are kind, funny, brilliant, and I know with them I am receiving the best care possible. They make it possible for me to understand and accept my cancer experience for what it is, and as a result I can jump back into my life with joy and enthusiasm.
UofU Patient
January 18, 2021
HUNTSMAN CANCER CENTER
Dr Vaklavas has been nothing short of a gift from God for me and my husband. He has been continuously kind, thoughtful, courteous, caring, and competent. He has provided me with clear explanations for everything that was going to occur as we fought my breast cancer. He has unfailingly listened to my concerns. He has always responded to my messages, whether by phone or via MyChart. He has treated me with the utmost respect. We will bless him forever for the person he is and the care he has provided.
UofU Patient
January 18, 2021
FARMINGTON HEALTH CENTER
THIS DR. IS AN EXCELLANT PEOPLE PERSON. HE TAKES THE TIME TO GO OVER ANY CONCERNS I HAVE AND ECPLAINS ALL THINGS IN DETAIL AND MAKES SURE I UNDERSTAND. I THINK HE IW WONDERFUL !!
UofU Patient
January 15, 2021
HUNTSMAN CANCER CENTER
Dr. Vaklavas is the best
UofU Patient
December 27, 2020
HUNTSMAN CANCER CENTER
He took the time to explain things!
UofU Patient
December 04, 2020
HUNTSMAN CANCER CENTER
Good Experience
UofU Patient
November 29, 2020
HUNTSMAN CANCER CENTER
Dr Vaklavas is one of the most engaged physicians I have met. He explained research and treatment options in depth.
UofU Patient
November 10, 2020
HUNTSMAN CANCER CENTER
Dr. Vaklavas is knowledgable and caring. The fellow that saw me was also very helpful.
UofU Patient
November 08, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
October 29, 2020
FARMINGTON HEALTH CENTER
The dr explained a lot and answered a lot of my queations . he is wonderful and i would highly reccomend him
UofU Patient
October 23, 2020
HUNTSMAN CANCER CENTER
A+ results
UofU Patient
October 12, 2020
HUNTSMAN CANCER CENTER
excellent. I really liked the doctor.
UofU Patient
September 23, 2020
FARMINGTON HEALTH CENTER
DR. VAKLAVAS IS AKWAYS KIND AND CONSIDERATE AND LISTENS TO MY CONCERNS AND THEN EXPLORES THRU THEM.
UofU Patient
September 23, 2020
HUNTSMAN CANCER CENTER
Super Amazing MD
UofU Patient
September 22, 2020
FARMINGTON HEALTH CENTER
I am so impressed with Dr Valklovas. He is wonderful!
UofU Patient
September 16, 2020
FARMINGTON HEALTH CENTER
he was very helpful
UofU Patient
September 12, 2020
HUNTSMAN CANCER CENTER
Dr.Vaklavas was wonderful. He explained my cancer and my options to me with compassion and clarity. He seemed very competent.
UofU Patient
July 21, 2020
HUNTSMAN CANCER CENTER
If I had to go through this terrible cancer experience, I thank God that Dr. Vaklavas was my doctor. He has been unbelievably kind, considerate and caring, he has explained the treatments fully, he has listened to all of my concerns, and he has involved me in treatment decisions. He has responded quickly to all of my messages, and he has shown tremendous heart and exceptional medical ability. I was able to withstand all of the brutal cancer treatments because he and his wonderful staff helped me to do it. My husband and I are grateful beyond words.
UofU Patient
July 20, 2020
FARMINGTON HEALTH CENTER
great
UofU Patient
June 30, 2020
HUNTSMAN CANCER CENTER
Very good experience with Dr. Valklavas.
UofU Patient
June 09, 2020
FARMINGTON HEALTH CENTER
this was the most accommodating and comprehensive appointment i have ever had
UofU Patient
June 02, 2020
HUNTSMAN CANCER CENTER
Dr. Voklovos is a brilliant, empathetic , generous , kind and a wonderful Oncologist. I would rate him No: 1 . The best
UofU Patient
May 18, 2020
HUNTSMAN CANCER CENTER
the doctor was very informative!!
UofU Patient
April 23, 2020
HUNTSMAN CANCER CENTER
They are very professional!
UofU Patient
April 21, 2020
HUNTSMAN CANCER CENTER
I feel a trusting deep connection with Dr. Vaklavas and I feel so comfortable. He's so kind. And he made me feel as if I mattered and that's very important to me.
UofU Patient
April 07, 2020
HUNTSMAN CANCER CENTER
Dr. Vaklavas is an exceptional physician. I've heard him called brilliant, gifted, conscientious, by his colleagues. I agree and in addition, I call him kind, caring, concerned about my well being, and respectful. If I had to go through this terrible ordeal, I'm so grateful that I have him and his staff by my side.
UofU Patient
March 27, 2020
FARMINGTON HEALTH CENTER
love Dr. V
UofU Patient
March 24, 2020
HUNTSMAN CANCER CENTER
all good
UofU Patient
March 23, 2020
FARMINGTON HEALTH CENTER
I was very impressed with Dr. V. He was great and very helpful and concerned about my health.
UofU Patient
March 04, 2020
FARMINGTON HEALTH CENTER
first time to see dr vaklava! excellent experience. answered all my concerns and explained things very well.
UofU Patient
February 25, 2020
HUNTSMAN CANCER CENTER
This provider is very knowledgeable and compassionate. very happy with him and trust his care.
Throughout his career, Dr. Vaklavas has developed a series of research activities in breast cancer that span the entire spectrum from lab-based research to clinical trials. In the lab, his focus has been on translation (mRNA to protein) and the discovery of compounds that disrupt oncogenic translation. This research has been supported by a Young Investigator Award from ASCO and a Career Catalyst Award in Basic and Translational Research from Susan G Komen.
As the Physician Leader in Breast Cancer at Huntsman Cancer Institute, he oversees all clinical research conducted in the Institute pertaining to breast cancer. He oversees the clinical trials portfolio and serves as the Principal Investigator for many clinical trials including investigator-initiated studies that intend to bring the highly innovative basic science conducted at Huntsman Cancer Institute closer to clinical applications.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Research Interests
- Functional Precision Oncology
- Translational Genomics
- Phase I and II Clinical Trials
- Platform Clinical Trials
- Breast Cancer
- Translation
Selected Publications - Journal Articles
Journal Article
- Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES (2021). An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. . Breast Cancer Res, 23(1).
- Chae YK, Hong F, Vaklavas C, Cheng HC, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, ODwyer PJ, Chen AP, Flaherty KT (2020). A Phase II Study of AZD4547 in Patients with Tumors harboring Aberrations in the FGFR Pathway: Results from the NCI-MATCH Trial (EAY131) Sub-protocol W. J Clin Oncol, 38(21), 2407-2417.
- Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A on behalf of the Translational Breast Cancer Research Consortium (2020). TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole with or without bevacizumab in post-menopausal women with newly diagnosed stage II/III hormone receptor positive and HER2 negative breast cancer. Breast Cancer Res, 22(1).
- Vaklavas C, Blume SW, Grizzle WE (2020). Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer. . Translational Oncology, 13(2), 452-470.
- Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V (2019). TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol, 37(9), 714-722.
- Vaklavas C, Zinn KR, Samuel SL, Meng Z, Grizzle WE, Choi H, Blume SW (2018). Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition. Oncol Rep, 39(6), 2482-2498.
- Vaklavas C, Blume SW, Grizzle WE (2017). Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development. Front Oncol, 7, 158.
- Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ (2016). Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget, 8(9), 16052-16074.
- Vaklavas C, Grizzle WE, Choi H, Meng Z, Zinn KR, Shrestha K, Blume SW (2016). IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells. Tumour Biol, 37(10), 13247-13264.
- Rugo HS, et al, I-SPY2 Investigators (2016). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 375(1), 23-34.
- Park JW, et al, I-SPY2 Investigators (2016). Adaptive Randomization of Neratinib in Early Breast Cancer. New England Journal of Medicine, 375(1), 11-22.
- Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE (2016). Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res, 4(5), 390-9.
- Morris GJ, Dawood S, Cortes J, Ward JH, Vaklavas C, Forero A, Ward S, Toppmeyer D (2015). Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat? Semin Oncol, 42(4), e67-79.
- Turner NC, et al, PALOMA3 Study Group (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine, 373(3), 209-19.
- Paoletti C, Li Y, Muiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF, Translational Breast Cancer Research Consortium TBCRC (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res, 21(12), 2771-9.
- Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, Translational Breast Cancer Research Consortium TBCRC (2015). TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res, 21(12), 2722-9.
- Vaklavas C, Meng Z, Choi H, Grizzle WE, Zinn KR, Blume SW (2015). Small molecule inhibitors of IRES-mediated translation. Cancer Biol Ther, 16(10), 1471-85.
- Vaklavas C, Forero A (2014). Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). BioDrugs, 28(3), 253-63.
- Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R (2014). Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology, 60(127), 1611-23.
- Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A (2013). Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. Cancer Biother Radiopharm, 28(5), 370-9.
- Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, Forero A, Ravi V, Patel S, Boudadi K, Chugh R, Morris GJ (2013). A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer. Semin Oncol, 40(2), 135-44.
- Vaklavas C, Forero-Torres A (2013). Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol, 3(4), 209-25.
- Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2011). Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer, 118(5), 1422-8.
- Vaklavas C, Ross JR, Nabell LM, Forero A, Heslin MJ, Wood TE (2012). By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes. J Natl Compr Canc Netw, 10(1), 7-13.
- Vaklavas C, Steciuk MR, Ren Y, Baird MF, Mikhail FM, Foran JM (2011). A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogenetics. Clin Lymphoma Myeloma Leuk, 11(6), 521-4.
- Vaklavas C, Forero-Torres A (2011). How do I treat "triple-negative" disease. Curr Treat Options Oncol, 12(4), 369-88.
- Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011). Common cardiovascular medications in cancer therapeutics. Pharmacol Ther, 130(2), 177-90.
- Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R (2010). Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer, 117(1), 77-85.
- Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM (2010). Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J, 7, 256.
- Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD (2010). Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf, 33(3), 171-87.
- Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ (2010). Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res, 16(4), 1149-58.
- Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM (2010). Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist, 15(2), 130-41.
- Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ (2009). Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. J Pediatr Hematol Oncol, 31(11), 803-11.
- Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R (2009). Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab, 94(11), 4423-32.
- Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD (2008). Molecular basis of statin-associated myopathy. Atherosclerosis, 202(1), 18-28.
- Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A (2006). 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res, 31(5), 691-4.
- Christakis C, Vaklavas C, Kontos N, Chatzidimitriou C, Tzelepi K, Karanikas M, Christakis E (2005). Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin grafts. Techniques in Coloproctology, 8 Suppl 1, s85-8.
Book Chapter
- Vaklavas C, LoBuglio AF, Saleh M, Yelin M, Forero A (2013). CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE). In Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 211-20). Springer.
- Forero A, Vaklavas C, LoBuglio AF (2013). Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies. In Antibody- Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 161-75). Springer.
Editorial
- Welm BE, Vaklavas C, Welm AL (2021). Toward improved models of human cancer. 5(1).
- Vaklavas C, Chatzizisis YS (2010). The changing perspective of cardiology in cancer care. Expert Rev Cardiovasc Ther, 9(1), 1-3.